Skip to main content
PMC home page
Archives of Disease in Childhood. Fetal and Neonatal Edition logoLink to Archives of Disease in Childhood. Fetal and Neonatal Edition
. 1998 Jul;79(1):F26–F33. doi: 10.1136/fn.79.1.f26

Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease

T Bhuta, A Ohlsson
PMCID: PMC1720811  PMID: 9797621

Abstract

AIM—To review systematically the evidence to determine whether dexamethasone treatment of very low birthweight infants begun within 14 days of age prevents chronic lung disease (CLD) without clinically significant side effects.
METHODS—Randomised controlled trials of dexamethasone started within this time frame were identified through a search of electronic databases, proceedings of scientific meetings, and personal files. Meta-analyses using event rate ratio (ERR), event rate difference (ERD), and if significant, numbers needed to treat (NNT) for benefits and numbers needed to harm (NNH) for adverse effects were calculated. Weighted mean difference were used for continuous variables. Three prespecified subgroup analyses were performed for; (i) dexamethasone begun within 36 hours (hours) of birth; (ii) dexamethasone initiated between 7-14 days of age; or (iii) if surfactant treatment was used.
RESULTS—Ten studies were included in the review; six where dexamethasone was initiated within 36 hours of age, four studies for dexamethasone started between 7 and 14 days and six studies using surfactant. Mortality ERR and NNT with 95% confidence intervals for dexamethasone initiated at 7-14 days of age were 0.35 (0.16, 0.74) and 8 (4,30). ERRs and NNTs for CLD at 28 days and 36 weeks of postmenstrual age were 0.71 (0.61, 0.84), 8 (5, 17), and 0.57 (0.44, 0.76), 10 (6, 23) in the overall analyses. When dexamethasone was started at 7 to 14 days of age ERR and NNT for CLD at 36 weeks were 0.63(0.47, 0.85) and 3 (2, 9). Clinically significant side effects included increased risk of hypertension, hyperglycaemia, and increased time to regain birthweight.
CONCLUSIONS—These meta-analyses show a significant reduction in risk of CLD at 28 days and 36 weeks of postmenstrual age. In the subgroup where dexamethasone was started between 7 and 14 days of age mortality was significantly reduced. Caution is warranted in the routine use of dexamethasone because of lack of data on long term neurodevelopmental outcomes.



Full Text

The Full Text of this article is available as a PDF (132.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avery G. B., Fletcher A. B., Kaplan M., Brudno D. S. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985 Jan;75(1):106–111. [PubMed] [Google Scholar]
  2. Brozanski B. S., Jones J. G., Gilmour C. H., Balsan M. J., Vazquez R. L., Israel B. A., Newman B., Mimouni F. B., Guthrie R. D. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. J Pediatr. 1995 May;126(5 Pt 1):769–776. doi: 10.1016/s0022-3476(95)70410-8. [DOI] [PubMed] [Google Scholar]
  3. Cummings J. J., D'Eugenio D. B., Gross S. J. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989 Jun 8;320(23):1505–1510. doi: 10.1056/NEJM198906083202301. [DOI] [PubMed] [Google Scholar]
  4. Durand M., Sardesai S., McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. Pediatrics. 1995 Apr;95(4):584–590. [PubMed] [Google Scholar]
  5. Ehrenkranz R. A. Steroids, chronic lung disease, and retinopathy of prematurity. Pediatrics. 1992 Oct;90(4):646–647. [PubMed] [Google Scholar]
  6. Fitzhardinge P. M., Eisen A., Lejtenyi C., Metrakos K., Ramsay M. Sequelae of early steroid administration to the newborn infant. Pediatrics. 1974 Jun;53(6):877–883. [PubMed] [Google Scholar]
  7. Groneck P., Reuss D., Götze-Speer B., Speer C. P. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. J Pediatr. 1993 Jun;122(6):938–944. doi: 10.1016/s0022-3476(09)90024-5. [DOI] [PubMed] [Google Scholar]
  8. Harkavy K. L., Scanlon J. W., Chowdhry P. K., Grylack L. J. Dexamethasone therapy for chronic lung disease in ventilator- and oxygen-dependent infants: a controlled trial. J Pediatr. 1989 Dec;115(6):979–983. doi: 10.1016/s0022-3476(89)80754-1. [DOI] [PubMed] [Google Scholar]
  9. Hennes H. M., Lee M. B., Rimm A. A., Shapiro D. L. Surfactant replacement therapy in respiratory distress syndrome. Meta-analysis of clinical trials of single-dose surfactant extracts. Am J Dis Child. 1991 Jan;145(1):102–104. doi: 10.1001/archpedi.1991.02160010108027. [DOI] [PubMed] [Google Scholar]
  10. Jobe A. H., Mitchell B. R., Gunkel J. H. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol. 1993 Feb;168(2):508–513. doi: 10.1016/0002-9378(93)90483-y. [DOI] [PubMed] [Google Scholar]
  11. Jobe A. H. Pulmonary surfactant therapy. N Engl J Med. 1993 Mar 25;328(12):861–868. doi: 10.1056/NEJM199303253281208. [DOI] [PubMed] [Google Scholar]
  12. Kari M. A., Heinonen K., Ikonen R. S., Koivisto M., Raivio K. O. Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia. Arch Dis Child. 1993 May;68(5 Spec No):566–569. doi: 10.1136/adc.68.5_spec_no.566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kendig J. W., Notter R. H., Cox C., Aschner J. L., Benn S., Bernstein R. M., Hendricks-Munoz K., Maniscalco W. M., Metlay L. A., Phelps D. L. Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials. Pediatrics. 1988 Nov;82(5):756–762. [PubMed] [Google Scholar]
  14. Long W., Thompson T., Sundell H., Schumacher R., Volberg F., Guthrie R. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. The American Exosurf Neonatal Study Group I. J Pediatr. 1991 Apr;118(4 Pt 1):595–605. doi: 10.1016/s0022-3476(05)83388-8. [DOI] [PubMed] [Google Scholar]
  15. Mammel M. C., Fiterman C., Coleman M., Boros S. J. Short-term dexamethasone therapy for bronchopulmonary dysplasia: acute effects and 1-year follow-up. Dev Pharmacol Ther. 1987;10(1):1–11. doi: 10.1159/000457722. [DOI] [PubMed] [Google Scholar]
  16. Mammel M. C., Green T. P., Johnson D. E., Thompson T. R. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983 Jun 18;1(8338):1356–1358. doi: 10.1016/s0140-6736(83)92139-6. [DOI] [PubMed] [Google Scholar]
  17. Merritt T. A., Hallman M., Bloom B. T., Berry C., Benirschke K., Sahn D., Key T., Edwards D., Jarvenpaa A. L., Pohjavuori M. Prophylactic treatment of very premature infants with human surfactant. N Engl J Med. 1986 Sep 25;315(13):785–790. doi: 10.1056/NEJM198609253151301. [DOI] [PubMed] [Google Scholar]
  18. Merritt T. A., Stuard I. D., Puccia J., Wood B., Edwards D. K., Finkelstein J., Shapiro D. L. Newborn tracheal aspirate cytology: classification during respiratory distress syndrome and bronchopulmonary dysplasia. J Pediatr. 1981 Jun;98(6):949–956. doi: 10.1016/s0022-3476(81)80603-8. [DOI] [PubMed] [Google Scholar]
  19. Mukwaya G. Immunosuppressive effects and infections associated with corticosteroid therapy. Pediatr Infect Dis J. 1988 Jul;7(7):499–504. doi: 10.1097/00006454-198807000-00011. [DOI] [PubMed] [Google Scholar]
  20. Ng P. C., Brownlee K. G., Dear P. R. Gastroduodenal perforation in preterm babies treated with dexamethasone for bronchopulmonary dysplasia. Arch Dis Child. 1991 Oct;66(10 Spec No):1164–1166. doi: 10.1136/adc.66.10_spec_no.1164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ng P. C. The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia. Arch Dis Child. 1993 Mar;68(3 Spec No):330–336. doi: 10.1136/adc.68.3_spec_no.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ogden B. E., Murphy S. A., Saunders G. C., Pathak D., Johnson J. D. Neonatal lung neutrophils and elastase/proteinase inhibitor imbalance. Am Rev Respir Dis. 1984 Nov;130(5):817–821. doi: 10.1164/arrd.1984.130.5.817. [DOI] [PubMed] [Google Scholar]
  23. Ohlsson A., Calvert S. A., Hosking M., Shennan A. T. Randomized controlled trial of dexamethasone treatment in very-low-birth-weight infants with ventilator-dependent chronic lung disease. Acta Paediatr. 1992 Oct;81(10):751–756. doi: 10.1111/j.1651-2227.1992.tb12096.x. [DOI] [PubMed] [Google Scholar]
  24. Rastogi A., Akintorin S. M., Bez M. L., Morales P., Pildes R. S. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics. 1996 Aug;98(2 Pt 1):204–210. [PubMed] [Google Scholar]
  25. Sanders R. J., Cox C., Phelps D. L., Sinkin R. A. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatr Res. 1994 Jul;36(1 Pt 1):122–128. doi: 10.1203/00006450-199407001-00022. [DOI] [PubMed] [Google Scholar]
  26. Schulz K. F., Chalmers I., Hayes R. J., Altman D. G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995 Feb 1;273(5):408–412. doi: 10.1001/jama.273.5.408. [DOI] [PubMed] [Google Scholar]
  27. Shinwell E. S., Karplus M., Zmora E., Reich D., Rothschild A., Blazer S., Bader D., Yurman S., Dolfin T., Kuint J. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1996 Jan;74(1):F33–F37. doi: 10.1136/fn.74.1.f33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tan K. L. Blood pressure in very low birth weight infants in the first 70 days of life. J Pediatr. 1988 Feb;112(2):266–270. doi: 10.1016/s0022-3476(88)80068-4. [DOI] [PubMed] [Google Scholar]
  29. Weichsel M. E., Jr The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurological hazards. Ann Neurol. 1977 Nov;2(5):364–366. doi: 10.1002/ana.410020503. [DOI] [PubMed] [Google Scholar]
  30. Werner J. C., Sicard R. E., Hansen T. W., Solomon E., Cowett R. M., Oh W. Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr. 1992 Feb;120(2 Pt 1):286–291. doi: 10.1016/s0022-3476(05)80446-9. [DOI] [PubMed] [Google Scholar]
  31. Wilson D. M., Baldwin R. B., Ariagno R. L. A randomized, placebo-controlled trial of effects of dexamethasone on hypothalamic-pituitary-adrenal axis in preterm infants. J Pediatr. 1988 Oct;113(4):764–768. doi: 10.1016/s0022-3476(88)80398-6. [DOI] [PubMed] [Google Scholar]
  32. Yeh T. F., Torre J. A., Rastogi A., Anyebuno M. A., Pildes R. S. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. J Pediatr. 1990 Aug;117(2 Pt 1):273–282. doi: 10.1016/s0022-3476(05)80547-5. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood. Fetal and Neonatal Edition are provided here courtesy of BMJ Publishing Group

RESOURCES